To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney disease on hemodialysis as measured by time to death.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
2,200
Time to Death
Time to Death attributable to cardiovascular disease
Number of hospitalizations for any cause
Number of hospitalizations due to cardiovascular disease
Number of days hospitalized for any cause
Number of days hospitalized due to cardiovascular disease
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Tuscaloosa Nephrology Associates
Tuscaloosa, Alabama, United States
Gambro Healthcare - Inglewood
Inglewood, California, United States
Gambro Healthcare - Los Angeles
Los Angeles, California, United States
Apex Research of Riverside
Riverside, California, United States
East Bay Nephrology Medical Group
San Pablo, California, United States
Nephrology Educational Services and Research, Inc.
Tarzana, California, United States
Lowry DaVita Dialysis Unit
Denver, Colorado, United States
Stamford Nephrology
Stamford, Connecticut, United States
Capital Dialysis Unit
Washington D.C., District of Columbia, United States
Capitol Dialysis
Washington D.C., District of Columbia, United States
...and 50 more locations